Hua Medicine
2026 Interim Results

August 2026

Copyright © Hua Medicine 2026

Disclaimer

This presentation contains forward-looking statements, including statements regarding our business strategy, clinical development plans, regulatory submissions, strategic initiatives, and other statements relating to our future business development and economic performance.

While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other statutory requirements may render actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, (1) general market, macro-economy, governmental and regulatory trends, (2) movements in local and international securities markets, currency exchange rates and interest rates, (3) competitive pressures, (4) technological developments, (5) changes in the financial position or creditworthiness of our customers, partners, vendors, obligors and counterparts, and changes in the developments in the markets in which the group operates, (6) legislative or regulatory developments, (7) management changes and changes to our business group structure and (8) other key factors that may adversely affect our business and financial model.

We are not under any obligation to (and expressly disclaim any such obligations to) update or alter forward-looking statements whether as a result of new information, future events, or otherwise.

This material may not be reproduced, distributed or transmitted to any other person or incorporated in any way into another document or other material without the prior written consent of us.

This document is not:
(a) an offer of securities for sale in Hong Kong or elsewhere; or
(b) an invitation to enter into an agreement to acquire, dispose of, subscribe for or underwrite securities, or to the issue of any securities.

All documents and conference contents are for institutional investors, no unauthorized audio and video recordings and may be directly or indirectly reproduced, even modified, redistributed or forwarded to any other person and may not be published in whole or in part for any purpose.


For the accuracy and completeness of the context, references to information related to products launched in China, labeling requirements, should follow the relevant documents approved by the Chinese regulatory authorities.

The above mentioned information should not be interpreted as a recommendation or promotion of any drug or treatment regimen or should it substitute for the medical advice of any healthcare professional. Please consult a healthcare professional for any matters related to medical treatment.

Copyright © Hua Medicine 2026

Strong Commercial Execution Led to Accelerated Growth

Sales of HuaTangNing® (Packs)




Key Commercial Highlights

- Expanded commercialization team to 262 personnel, strengthening commercial execution
- Expect continued growth momentum following sustained strong half-on-half (HoH) growth rate
- Top regions continued to deliver strong growth, reflecting substantial potential for further market penetration

Copyright © Hua Medicine 2026


Key Milestones Achieved in Our Asian Market Expansion



- NRDL price maintained for 9

Advancing Our Global Expansion Strategy from China across Southeast Asia, Belt and Road Markets and Beyond

Copyright © Hua Medicine 2026



Synergistic Combinations with Promising Multiple Metabolic Benefits


Three combination therapy studies in animal models, presented at 2026 ADA


Synergistic Glycemic Control with Dose Sparing Potential


Superior glucose-lowering effects, efficacy of low-dose combinations was comparable to high-dose monotherapy.


Orforglipron amplified dorzagliatin-

function and hepatic glucose











Copyright © Hua Medicine 2026


frontiers


DIABETES
OBESITY AND
METABOLISM
ORIGINAL ARTICLE
Genetic evidence for
activation on frailty-related outcomes: A Mende
randomisation study
Rong Hua MPhil, Mai Shi PhD, Elaine Chow PhD, Aimin Yang Phi
Yin Ting Cheung PhD
First published: 04 March 2025
https://doi.org/10.1111/dom.163


American
Check for updates


WILEY
Research Article
Efficacy of Dorzagliatin and Related Factors in a Real-World
Cohort of Type 2 Diabetes

Global 2nd Generation GKA Leads U.S. Expansion

Dorzagliatin: Second Generation

Acceleration in technology to advance medicine

Advancing 2nd Generation GKA


Integrating AI To Empower Our Business

Financial Section

Sustainable Revenue Growth and Continued Improved Cost Efficiency

Revenue (RMB Millions)


- Sales revenue increased by 74% YoY



With expansion of our commercialization team and hospital coverage, revenue rose 74% year-on-year to RMB378.9 million, reflecting the successful implementation of our in-house commercialization strategy.

Gross Profit (RMB Millions) and Gross Margin


- Gross margin continued increased to 61.8%



As manufacturing scale expanded and cost efficiencies improved, gross profit increased by 99% to RMB234.3 million, with gross margin rising 7.6 percentage points to 61.8% compared with the same period in 2025.

Selling Expenses (RMB Millions) and % of Revenue

- Sales expense ratio moved into a stable range



As the commercialization team has been fully established, the ratio of selling expense to revenue increased by four percentage points from 29.5% in the first half of 2025 to 33.5% in the reporting period, normalizing to a sustainable range.

Copyright © Hua Medicine 2026

R&D and Administrative Expenses Under Control

R&D Expenses (RMB Millions) and % of Revenue

- *R&D expenses remained stable*

Administrative Expenses (RMB Millions) and % of Revenue

- *Administrative expenses ratio declines 6.6 pct*


R&D expenses increased by RMB1.0 million, the change is attributable to the advancement of the 2nd generation GKA project

Copyright © Hua Medicine 2026

Increasing Profitability

Commercialization Efforts Achieved Profits* (RMB Millions)

- Commercialization efforts achieved profit doubled




(Note: *Defined by gross profit less selling expenses)

Driven by enhanced operational efficiency, our commercialization efforts achieved profit of approximately RMB107.4 million, doubled from RMB53.7 million in the same period of 2025.

Net Profit (RMB Millions)

- Net loss on an adjusted basis is narrowed




(Note: *Pro Forma for the elimination of approximately RMB1.2 billion unamortized liabilities upon termination of the Bayer agreement on January 1, 2025)

Excluding the effect of the one-off release of contract liabilities to other income of approximately RMB1,243.5 million in 2025 following WKH WHUPLQDWLRQ RI WKH %D\HU FRQWUDFW W QDUURZHG E\ DSSUR[LPDWHO\ 50% 7KH QDUURZ loss on an adjusted basis is mainly attributable to the increase in revenue and improved gross profit margin.

Copyright © Hua Medicine 2026

Strong Cash Position

Cash Balance (RMB Millions)



- Cash balance remained robust. Bank balances and cash position was approximately RMB1,072.9 million as of June 30, 2025, representing a decrease of only RMB39.3 million from the end of 2025.
- Building on the strong commercial momentum of Hua Tanning® (华芪宁®) in mainland China, the business is now generating robust cash flows that allow us to step up investment across the business and lay the foundation for accelerated growth.
- Our primary use of cash is to fund our commercialization efforts, manufacturing expenses, research and development expenses, regulatory and other clinical trial costs, and related supporting administration.

Copyright © Hua Medicine 2026

Value Drivers and Key Milestones in the Near Future



Accelerating Commercial Momentum with Expanding Market Reach

- Employee incentive-linked revenue targets set at RMB 900M for 2026
- Planned market launch in Macao in 2H2026
- Expected NDA for dorzagliatin and metformin FDC in 2027

Anticipated Clinical Progress with High-Value Data Milestones

- Data readout of Phase 1b MAD of 2nd Gen GKA in 2H2026
- Expected IND for MODY-2 in 2H2026
- Expected IND for Fatty Liver in 2H2026
- More publications of ongoing real world studies

Strategic Partnerships to Drive Pipeline Depth and Diversification

- Will pursue partnerships to develop the 2nd generation GKA for global markets
- Potential pipeline expansion through in-licensing in 2H2026

Copyright © Hua Medicine 2026



Hua Medicine